Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity.
paper
Cited
Public
Unavailable
- Authors
- Dempsey, Delia; Tutka, Piotr; Jacob, Peyton; Allen, Faith; Schoedel, Kerri; Tyndale, Rachel F; Benowitz, Neal L
- Year
- 2004
- Journal
- Clinical pharmacology and therapeutics
- PMID
- 15229465
- DOI
- 10.1016/j.clpt.2004.02.011
BACKGROUND: Nicotine and a variety of other drugs and toxins are metabolized by cytochrome P450 (CYP) 2A6. Our objective was to evaluate the use of oral nicotine with measurement of the trans-3'-hydroxycotinine (3HC)/cotinine (COT) metabolite ratio as a noninvasive probe of CYP2A6 activity. METHODS: Sixty-two healthy volunteers received an oral solution of deuterium-labeled nicotine (2 mg) and its metabolite cotinine (10 mg). Plasma nicotine and plasma and saliva cotinine and 3HC concentrations were measured over time. RESULTS: The 3HC/COT ratio derived from deuterium-labeled cotinine, measured in either plasma (2-8 hours after administration) or saliva (at 6 hours), was strongly correlated with the oral clearance of nicotine (r = 0.76-0.83, depending on the time of measurement). The 6-hour 3HC/COT ratio from nicotine derived from tobacco in 14 smokers was highly correlated with the ratio derived from deuterium-labeled nicotine (r = 0.88) and was also highly correlated with the oral clearance of nicotine (r = 0.90). Two subjects homozygous for inactive CYP2A6 alleles produced no 3HC, confirming the specificity of the metabolite ratio. The 3HC/COT ratio was also highly correlated with the clearance and half-life of cotinine, consistent with the fact that cotinine is also primarily metabolized by CYP2A6. CONCLUSIONS: The 3HC/COT ratio derived from nicotine either administered as a probe drug or from tobacco use, measured in either plasma or saliva, is highly correlated with the oral clearance of nicotine. The ratio appears to be a useful noninvasive marker of the rate of nicotine metabolism (which is important in studying nicotine addiction and smoking behavior), as well as a general marker of CYP2A6 activity (which is important in studying drug and toxin metabolism).
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Deep multi-omics profiling reveals three molecular subtypes of chronic obstructive pulmonary disease in a unique biomass-exposed Chinese population. | Wu W et al. | β | 2026 | β |
| Hydrogel Encapsulation of a Designed Fluorescent Protein Biosensor for Continuous Measurements of Sub-100 nM Nicotine. | Nichols AL et al. | β | 2026 | β |
| A multi-site study examining the tobacco withdrawal trajectory in people with tobacco and cannabis co-use. | Rabin RA et al. | β | 2025 | β |
| A phenome-wide association study of genetically determined nicotine metabolism reveals novel links with health-related outcomes. | Buchwald J et al. | β | 2025 | β |
| Cotinine, trans-3'-hydroxycotinine, and nicotine metabolite ratio indicate association between smoking and tooth loss. | Zhang Y et al. | β | 2025 | β |
| CYP2A6 Activity and Deuterated 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) Metabolism in Cigarette Smokers. | von Weymarn LB et al. | β | 2025 | β |
| Disentangling the effects of nicotine versus non-nicotine constituents of tobacco smoke on major depressive disorder: A multivariable Mendelian randomisation study. | Burke C et al. | β | 2025 | β |
| Extending Investigations of miR-126-5p on the Regulation of CYP2A6, the Major Nicotine-Inactivating Enzyme. | Gu W et al. | β | 2025 | β |
| Nicotine promotes AngII-induced abdominal aortic aortopathies in female and male mice: role of sex hormones. | Ensor M et al. | β | 2025 | β |
| Physiologically Based Pharmacokinetic Modeling to Predict Nicotine Pharmacokinetics of Nicotine Pouches Under Naturalistic Use Conditions. | Salehi A et al. | β | 2025 | β |
| Simulating early steps in nicotine dependence: Pharmacokinetics, activation, and chaperoning of nicotinic receptors. | Wang AZ et al. | β | 2025 | β |
| The effect of cut sizes and pH of tobacco leaf in smokeless tobacco products on the pharmacokinetics of nicotine. | Fu Y et al. | β | 2025 | β |
| The Impact of CYP2D6 metabolizer phenotypes on the EDDP/methadone metabolic ratio: A comprehensive analysis. | Wilmes V et al. | β | 2025 | β |
| Chronic Exposure to E-Cigarettes Elevates CYP2A5 Activity, Protein Expression, and Cotinine-Induced Production of Reactive Oxygen Species in Mice. | Kanamori K et al. | β | 2024 | β |
| CYP2A6 associates with respiratory disease risk and younger age of diagnosis: a phenome-wide association Mendelian Randomization study. | Giratallah H et al. | β | 2024 | β |
| Estimating the health impact of nicotine exposure by dissecting the effects of nicotine versus non-nicotine constituents of tobacco smoke: A multivariable Mendelian randomisation study. | Khouja JN et al. | β | 2024 | β |
| Feasibility of precision smoking treatment in a low-income community setting: results of a pilot randomized controlled trial in The Southern Community Cohort Study. | Lee SS et al. | β | 2024 | β |
| Geographic variation of mutagenic exposures in kidney cancer genomes. | Senkin S et al. | β | 2024 | β |
| Implementing a Metabolism-informed approach for smoking cessation in an Alaska Tribal health system: study protocol for a single-arm implementation pilot trial. | Jansen KJ et al. | β | 2024 | β |
| Interactive computational and experimental approaches improve the sensitivity of periplasmic binding protein-based nicotine biosensors for measurements in biofluids. | Haloi N et al. | β | 2024 | β |
| Is the nicotine metabolite ratio a useful tool to improve the effectiveness, safety, and adherence to quitting smoking? Systematic review of the literature and meta-analysis. | de Granda-Orive JI et al. | β | 2024 | β |
| Nicotine Metabolite Ratio Decreases After Switching Off Efavirenz-Based Therapy in People With HIV Who Smoke. | Medaglio D et al. | β | 2024 | β |
| Pharmacokinetics and Pharmacodynamics of Inhaled Nicotine Salt and Free-Base Using an E-cigarette: A Randomized Crossover Study. | Christen SE et al. | β | 2024 | β |
| PharmVar GeneFocus: CYP2A6. | Langlois AWR et al. | β | 2024 | β |
| Plasma nicotine and its metabolite as biomarkers of tobacco exposure and their relevance to pulmonary nodule. | Wang N et al. | β | 2024 | β |
| Small pouches, but high nicotine doses-nicotine delivery and acute effects after use of tobacco-free nicotine pouches. | Mallock-Ohnesorg N et al. | β | 2024 | β |
| The hidden impact: the rate of nicotine metabolism and kidney health. | Wang X et al. | β | 2024 | β |
| Urine levels of nicotine and its metabolites in young population exposed to second-hand smoke in nightclubs: a pilot study. | ZeΔiΔ A et al. | β | 2024 | β |
| Biochemical validation of self-reported electronic nicotine delivery system and tobacco heaviness of use. | Addicott MA et al. | β | 2023 | β |
| Biomarkers of exposure in urine of active smokers, non-smokers, and vapers. | Gallart-Mateu D et al. | β | 2023 | β |
| Can Treatment Support Mitigate Nicotine Metabolism-Based Disparities in Smoking Abstinence? Secondary Analysis of the Helping HAND 4 Trial. | Lee SS et al. | β | 2023 | β |
| CYP2C19 Plays a Major Role in the Hepatic <i>N</i>-Oxidation of Cotinine. | Perez-Paramo YX et al. | β | 2023 | β |
| Drug exposure during pregnancy: Current understanding and approaches to measure maternal-fetal drug exposure. | Hudson RE et al. | β | 2023 | β |
| Efficacy of insula deep repetitive transcranial magnetic stimulation combined with varenicline for smoking cessation: A randomized, double-blind, sham controlled trial. | Ibrahim C et al. | β | 2023 | β |
| Exploring Potential for a Personalized Medicine Approach to Smoking Cessation With an American Indian Tribe. | Carroll DM et al. | β | 2023 | β |
| Impact of Genetic Variants in the Nicotine Metabolism Pathway on Nicotine Metabolite Levels in Smokers. | Perez-Paramo YX et al. | β | 2023 | β |
| Influence of CYP2A6 Genetic Variation, Nicotine Dependence Severity, and Treatment on Smoking Cessation Success. | Chenoweth MJ et al. | β | 2023 | β |
| Pharmacokinetics of freebase nicotine and nicotine salts following subcutaneous administration in male rats. | Han S et al. | β | 2023 | β |
| Psychopharmacology of smoking cessation medications: focus on patients with mental health disorders. | Castaldelli-Maia JM et al. | β | 2023 | β |
| Simultaneous Measurement and Distribution Analysis of Urinary Nicotine, Cotinine, Trans-3'-Hydroxycotinine, Nornicotine, Anabasine, and Total Nicotine Equivalents in a Large Korean Population. | Lee HS et al. | β | 2023 | β |
| The Associations of <i>Trans</i>-3'-Hydroxy Cotinine, Cotinine, and the Nicotine Metabolite Ratio in Pediatric Patients with Tobacco Smoke Exposure. | Mahabee-Gittens EM et al. | β | 2023 | β |
| The use of biomarkers to guide precision treatment for tobacco use. | Siegel SD et al. | β | 2023 | β |
| Threshold for the pleasurable effects of nicotine are lower than its reinforcing effects during self-administration. | MacLean RR et al. | β | 2023 | β |
| Two Different Heated Tobacco Products vs. Cigarettes: Comparison of Nicotine Delivery and Subjective Effects in Experienced Users. | Vukas J et al. | β | 2023 | β |
| Usage Pattern and Nicotine Delivery during Ad Libitum Consumption of Pod E-Cigarettes and Heated Tobacco Products. | Rabenstein A et al. | β | 2023 | β |
| Variability in Urinary Nicotine Exposure Biomarker Levels Between Waves 1 (2013-2014) and 2 (2014-2015) in the Population Assessment of Tobacco and Health Study. | Ashley DL et al. | β | 2023 | β |
| Variation in Nicotine Metabolization According to Biological Factors and Type of Nicotine Consumer. | PΓ©rez-MartΓn H et al. | β | 2023 | β |
| Accuracy and applications of sequencing and genotyping approaches for CYP2A6 and homologous genes. | Langlois AWR et al. | β | 2022 | β |
| Agreement between nicotine metabolites in blood and self-reported smoking status: The Netherlands Epidemiology of Obesity study. | Folpmers S et al. | β | 2022 | β |
| Associations of biomarkers for exposure to tobacco smoke with lung cancer risk in Korea. | Kim GH et al. | β | 2022 | β |
| Brief Report: HIV Infection Does Not Explain Higher Nicotine Metabolism in People Living With HIV. | Arens Y et al. | β | 2022 | β |
| Brief Report: Nicotine Metabolism Ratio Increases in HIV-Positive Smokers on Effective Antiretroviral Therapy: A Cohort Study. | Bien-Gund CH et al. | β | 2022 | β |
| Cigarette Smoke Exposure and Acute Respiratory Distress Syndrome in Sepsis: Epidemiology, Clinical Features, and Biologic Markers. | Moazed F et al. | β | 2022 | β |
| Correlates of the nicotine metabolite ratio in Alaska Native people who smoke cigarettes. | Vogel EA et al. | β | 2022 | β |
| Evaluation of the nicotine metabolite ratio in smoking patients treated with varenicline and bupropion. | Tomaz PRX et al. | β | 2022 | β |
| Fluorescence activation mechanism and imaging of drug permeation with new sensors for smoking-cessation ligands. | Nichols AL et al. | β | 2022 | β |
| Functional characterization of novel rare CYP2A6 variants and potential implications for clinical outcomes. | El-Boraie A et al. | β | 2022 | β |
| Maternal nicotine metabolism moderates the impact of maternal cigarette smoking on infant birth weight: A Collaborative Perinatal Project investigation. | Stroud LR et al. | β | 2022 | β |
| Predicting nicotine metabolism across ancestries using genotypes. | Baurley JW et al. | β | 2022 | β |
| Review of HPLC-MS methods for the analysis of nicotine and its active metabolite cotinine in various biological matrices. | Jin S et al. | β | 2022 | β |
| Serum Concentrations of Cotinine and Trans-3'-Hydroxycotinine in US Adults: Results From Wave 1 (2013-2014) of the Population Assessment of Tobacco and Health Study. | Sosnoff CS et al. | β | 2022 | β |
| Stability of Varenicline Concentration in Saliva Over 21 Days at Three Storage Temperatures. | Novalen M et al. | β | 2022 | β |
| Acute effects of a very low nicotine content cigarette on laboratory smoking lapse: Impacts of nicotine metabolism and nicotine dependence. | Schlagintweit HE et al. | β | 2021 | β |
| A Genome-Wide Association Study of Nausea Incidence in Varenicline-Treated Cigarette Smokers. | Chenoweth MJ et al. | β | 2021 | β |
| Analyses of nicotine metabolism biomarker genetics stratified by sex in African and European Americans. | Chenoweth MJ et al. | β | 2021 | β |
| Biomarkers of Toxicant Exposure and Inflammation Among Women of Reproductive Age Who Use Electronic or Conventional Cigarettes. | Perez MF et al. | β | 2021 | β |
| Comparing the Rate of Nicotine Metabolism Among Smokers With Current or Past Major Depressive Disorder. | Schnoll R et al. | β | 2021 | β |
| Differences in exposure to toxic and/or carcinogenic volatile organic compounds between Black and White cigarette smokers. | St Helen G et al. | β | 2021 | β |
| Effect of race and glucuronidation rates on the relationship between nicotine metabolite ratio and nicotine clearance. | Liakoni E et al. | β | 2021 | β |
| Genetic Variants in Smoking-Related Genes in Two Smoking Cessation Programs: A Cross-Sectional Study. | PΓ©rez-Rubio G et al. | β | 2021 | β |
| Genome-wide association meta-analysis of nicotine metabolism and cigarette consumption measures in smokers of European descent. | Buchwald J et al. | β | 2021 | β |
| Impact of CYP2A6 Activity on Nicotine Reinforcement and Cue-Reactivity in Daily Smokers. | Butler K et al. | β | 2021 | β |
| Multiethnic Prediction of Nicotine Biomarkers and Association With Nicotine Dependence. | Bergen AW et al. | β | 2021 | β |
| New Biomarkers Based on Smoking-Related Phenotypes for Smoking Cessation Outcomes of Nicotine Replacement Therapy: A Prospective Study. | Nikkholgh A et al. | β | 2021 | β |
| Nicotine delivery and relief of craving after consumption of European JUUL e-cigarettes prior and after pod modification. | Mallock N et al. | β | 2021 | β |
| Nicotine metabolite ratio: Comparison of the three urinary versions to the plasma version and nicotine clearance in three clinical studies. | Giratallah HK et al. | β | 2021 | β |
| Pharmacogenetics factors influencing smoking cessation success; the importance of nicotine metabolism. | Perez-Paramo YX et al. | β | 2021 | β |
| Predicting Nicotine Metabolism Across Ancestries Using Genotypes | Baurley JW et al. | β | 2021 | β |
| Rapid, sensitive, and reliable quantitation of nicotine and its main metabolites cotinine and trans-3'-hydroxycotinine by LC-MS/MS: Method development and validation for human plasma. | Mallock N et al. | β | 2021 | β |
| The Role of Pharmacogenetics in Smoking. | El-Boraie A et al. | β | 2021 | β |
| Transferability of Ancestry-Specific and Cross-Ancestry CYP2A6 Activity Genetic Risk Scores in African and European Populations. | El-Boraie A et al. | β | 2021 | β |
| A prospective study of the association between rate of nicotine metabolism and alcohol use in tobacco users in the United States. | Roberts W et al. | β | 2020 | β |
| Associations Between Nicotine Metabolite Ratio and Gender With Transitions in Cigarette Smoking Status and E-Cigarette Use: Findings Across Waves 1 and 2 of the Population Assessment of Tobacco and Health (PATH) Study. | Verplaetse TL et al. | β | 2020 | β |
| Changes in Nicotine Metabolite Ratio Among Daily Smokers Receiving Treatment for Alcohol Use Disorder. | Dermody SS et al. | β | 2020 | β |
| Cigarette Smoking and ARDS After Blunt Trauma: The Influence of Changing Smoking Patterns and Resuscitation Practices. | Moazed F et al. | β | 2020 | β |
| Effects of Nicotine Metabolic Rate on Cigarette Reinforcement. | Liakoni E et al. | β | 2020 | β |
| Evaluation of a weighted genetic risk score for the prediction of biomarkers of CYP2A6 activity. | El-Boraie A et al. | β | 2020 | β |
| Impact of early nausea on varenicline adherence and smoking cessation. | Peng AR et al. | β | 2020 | β |
| Korean male active smokers: quantifying their smoking habits and the transformation factor among biomarkers in urine and blood. | Yang J et al. | β | 2020 | β |
| More than Smoke and Patches: The Quest for Pharmacotherapies to Treat Tobacco Use Disorder. | Moerke MJ et al. | β | 2020 | β |
| Pharmacokinetic Profile of Spectrum Reduced Nicotine Cigarettes. | Kamens HM et al. | β | 2020 | β |
| Postnatal Smoke Exposure Further Increases the Hepatic Nicotine Metabolism in Prenatally Smoke Exposed Male Offspring and Is Linked with Aberrant <i>Cyp2a5</i> Methylation. | Lkhagvadorj K et al. | β | 2020 | β |
| Precision nicotine metabolism-informed care for smoking cessation in Crohn's disease: A pilot study. | Scoville EA et al. | β | 2020 | β |
| Pregnant Smokers Receiving Opioid Agonist Therapy Have an Elevated Nicotine Metabolite Ratio: A Replication Study. | Kranzler HR et al. | β | 2020 | β |
| Prenatal smoke exposure induces persistent <i>Cyp2a5</i> methylation and increases nicotine metabolism in the liver of neonatal and adult male offspring. | Lkhagvadorj K et al. | β | 2020 | β |
| Relating individual differences in nicotine dependence severity to underpinning motivational and pharmacological processes among smokers from vulnerable populations. | Higgins ST et al. | β | 2020 | β |
| Relationships between the Nicotine Metabolite Ratio and a Panel of Exposure and Effect Biomarkers: Findings from Two Studies of U.S. Commercial Cigarette Smokers. | Carroll DM et al. | β | 2020 | β |
| The influence of nicotine metabolic rate on working memory over 6Β hours of abstinence from nicotine. | Nardone N et al. | β | 2020 | β |
| Urine Metabolites for Estimating Daily Intake of Nicotine From Cigarette Smoking. | Benowitz NL et al. | β | 2020 | β |
| Black Light Smokers: How Nicotine Intake and Carcinogen Exposure Differ Across Various Biobehavioral Factors. | St Helen G et al. | β | 2019 | β |
| Current advances in research in treatment and recovery: Nicotine addiction. | Prochaska JJ et al. | β | 2019 | β |
| Determining the pharmacokinetics of nicotinic drugs in the endoplasmic reticulum using biosensors. | Shivange AV et al. | β | 2019 | β |
| Does the nicotine metabolite ratio moderate smoking cessation treatment outcomes in real-world settings? A prospective study. | Shahab L et al. | β | 2019 | β |
| Effects of Nicotine Metabolic Rate on Withdrawal Symptoms and Response to Cigarette Smoking After Abstinence. | Liakoni E et al. | β | 2019 | β |
| Epigenome-wide association study of serum cotinine in current smokers reveals novel genetically driven loci. | Gupta R et al. | β | 2019 | β |
| Evaluating metronidazole as a novel, safe CYP2A6 phenotyping probe in healthy adults. | Stancil SL et al. | β | 2019 | β |
| Factors That Explain Differences in Abstinence Between Black and White Smokers: A Prospective Intervention Study. | Nollen NL et al. | β | 2019 | β |
| Nicotine-<i>N</i>'-Oxidation by Flavin Monooxygenase Enzymes. | Perez-Paramo YX et al. | β | 2019 | β |
| Nicotine Metabolism in Adults With Type 2 Diabetes. | Keith RJ et al. | β | 2019 | β |
| Nicotine Pharmacokinetics in Rat Brain and Blood by Simultaneous Microdialysis, Stable-Isotope Labeling, and UHPLC-HRMS: Determination of Nicotine Metabolites. | Xu Y et al. | β | 2019 | β |
| Relationship between skin melanin index and nicotine pharmacokinetics in African American smokers. | Liakoni E et al. | β | 2019 | β |
| Saliva cotinine concentrations in pregnant women who smoke and use nicotine patches. | Claire R et al. | β | 2019 | β |
| Smoking Cessation Pharmacotherapy Based on Genetically-Informed Biomarkers: What is the Evidence? | Panagiotou OA et al. | β | 2019 | β |
| The neurobiology of addiction. | Uhl GR et al. | β | 2019 | β |
| The relationship between nicotine metabolism and nicotine and carcinogen exposure among American Indian commercial cigarette smokers and electronic nicotine delivery system users. | Carroll DM et al. | β | 2019 | β |
| Using DNA methylation to validate an electronic medical record phenotype for smoking. | McGinnis KA et al. | β | 2019 | β |
| A Comparison of Direct and Indirect Analytical Approaches to Measuring Total Nicotine Equivalents in Urine. | Taghavi T et al. | β | 2018 | β |
| Acute effects of inhaled menthol on the rewarding effects of intravenous nicotine in smokers. | Valentine GW et al. | β | 2018 | β |
| Association of Reduced Nicotine Content Cigarettes With Smoking Behaviors and Biomarkers of Exposure Among Slow and Fast Nicotine Metabolizers: A Nonrandomized Clinical Trial. | Mercincavage M et al. | β | 2018 | β |
| Biosignature Discovery for Substance Use Disorders Using Statistical Learning. | Baurley JW et al. | β | 2018 | β |
| Cigarette consumption and biomarkers of nicotine exposure during pregnancy and postpartum. | Taghavi T et al. | β | 2018 | β |
| Comparing Smoking Topography and Subjective Measures of Usual Brand Cigarettes Between Pregnant and Non-Pregnant Smokers. | Bergeria CL et al. | β | 2018 | β |
| Electronic cigarette-generated aldehydes: The contribution of e-liquid components to their formation and the use of urinary aldehyde metabolites as biomarkers of exposure. | Conklin DJ et al. | β | 2018 | β |
| From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation. | Salloum NC et al. | β | 2018 | β |
| Genome-wide association study of a nicotine metabolism biomarker in African American smokers: impact of chromosome 19 genetic influences. | Chenoweth MJ et al. | β | 2018 | β |
| Influence of Nicotine Metabolism Ratio on [11C]-(+)-PHNO PET Binding in Tobacco Smokers. | Di Ciano P et al. | β | 2018 | β |
| Longitudinal Influence of Pregnancy on Nicotine Metabolic Pathways. | Taghavi T et al. | β | 2018 | β |
| Lung Microbiota Is Related to Smoking Status and to Development of Acute Respiratory Distress Syndrome in Critically Ill Trauma Patients. | Panzer AR et al. | β | 2018 | β |
| Nicotine Metabolism-informed Care for Smoking Cessation: A Pilot Precision RCT. | Wells QS et al. | β | 2018 | β |
| Nicotine metabolite ratio predicts smoking topography: The Pennsylvania Adult Smoking Study. | Chen A et al. | β | 2018 | β |
| Nicotine pharmacokinetics of electronic cigarettes: A review of the literature. | Fearon IM et al. | β | 2018 | β |
| Novel CYP2A6 diplotypes identified through next-generation sequencing are associated with in-vitro and in-vivo nicotine metabolism. | Tanner JA et al. | β | 2018 | β |
| P450 Pharmacogenetics in Indigenous North American Populations. | Henderson LM et al. | β | 2018 | β |
| Pharmacokinetic characterization of three novel 4-mg nicotine lozengesβ©. | Sukhija M et al. | β | 2018 | β |
| Platelet aggregation after blunt trauma is associated with the acute respiratory distress syndrome and altered by cigarette smoke exposure. | Moazed F et al. | β | 2018 | β |
| Predicting smoking abstinence with biological and self-report measures of adherence to varenicline: Impact on pharmacogenetic trial outcomes. | Peng AR et al. | β | 2018 | β |
| Pregnancy- Associated Changes in Pharmacokinetics and their Clinical Implications. | Koren G et al. | β | 2018 | β |
| Preparing the Way: Exploiting Genomic Medicine to Stop Smoking. | Bierut LJ et al. | β | 2018 | β |
| The Value of Biosamples in Smoking Cessation Trials: A Review of Genetic, Metabolomic, and Epigenetic Findings. | Saccone NL et al. | β | 2018 | β |
| Varenicline and Bupropion for Long-Term Smoking Cessation (the MATCH Study): Protocol for a Real-World, Pragmatic, Randomized Controlled Trial. | Zawertailo L et al. | β | 2018 | β |
| A liquidΒ chromatography-tandem mass spectrometry analysis of nine cytochrome P450 probe drugs and their corresponding metabolites in human serum and urine. | Puris E et al. | β | 2017 | β |
| A protocadherin gene cluster regulatory variant is associated with nicotine withdrawal and the urge to smoke. | Jensen KP et al. | β | 2017 | β |
| Characterising the nicotine metabolite ratio and its association with treatment choice: A cross sectional analysis of Stop Smoking Services in England. | Shahab L et al. | β | 2017 | β |
| CYP2A6 Genetic Variation Alters Striatal-Cingulate Circuits, Network Hubs, and Executive Processing in Smokers. | Li S et al. | β | 2017 | β |
| Distribution of polymorphic variants of CYP2A6 and their involvement in nicotine addiction. | LΓ³pez-Flores LA et al. | β | 2017 | β |
| Does menthol cigarette use moderate the effect of nicotine metabolism on short-term smoking cessation? | Jao NC et al. | β | 2017 | β |
| Effect of UGT2B10, UGT2B17, FMO3, and OCT2 genetic variation on nicotine and cotinine pharmacokinetics and smoking in African Americans. | Taghavi T et al. | β | 2017 | β |
| Exposure to Nicotine and Selected Toxicants in Cigarette Smokers Who Switched to Electronic Cigarettes: A Longitudinal Within-Subjects Observational Study. | Goniewicz ML et al. | β | 2017 | β |
| Genetic polymorphisms in CYP2A6 are associated with a risk of cigarette smoking and predispose to smoking at younger ages. | PΓ©rez-Rubio G et al. | β | 2017 | β |
| High Level of Tobacco Carcinogen-Derived DNA Damage in Oral Cells Is an Independent Predictor of Oral/Head and Neck Cancer Risk in Smokers. | Khariwala SS et al. | β | 2017 | β |
| Interaction between cytochrome P450 2A6 and Catechol-O-Methyltransferase genes and their association with smoking risk in young men. | Ou WC et al. | β | 2017 | β |
| Measures and predictors of varenicline adherence in the treatment of nicotine dependence. | Peng AR et al. | β | 2017 | β |
| Nicotine biomarkers and rate of nicotine metabolism among cigarette smokers taking buprenorphine for opioid dependency. | Gubner NR et al. | β | 2017 | β |
| Nicotine Metabolite Ratio (NMR) Prospectively Predicts Smoking Relapse: Longitudinal Findings From ITC Surveys in Five Countries. | Fix BV et al. | β | 2017 | β |
| Pharmacogenetic Optimization of Smoking Cessation Treatment. | Chenoweth MJ et al. | β | 2017 | β |
| Pharmacokinetics of nicotine following the controlled use of a prototype novel tobacco vapor product. | Yuki D et al. | β | 2017 | β |
| Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers. | Schuit E et al. | β | 2017 | β |
| Precision medicine and pharmacogenetics: what does oncology have that addiction medicine does not? | Kranzler HR et al. | β | 2017 | β |
| Reduced-Nicotine Cigarettes in Young Smokers: Impact of Nicotine Metabolism on Nicotine Dose Effects. | Faulkner P et al. | β | 2017 | β |
| Urine Cotinine Screening Detects Nearly Ubiquitous Tobacco Smoke Exposure in Urban Adolescents. | Benowitz NL et al. | β | 2017 | β |
| Variation in CYP2A6 Activity and Personalized Medicine. | Tanner JA et al. | β | 2017 | β |
| Variation in CYP2A6 and nicotine metabolism among two American Indian tribal groups differing in smoking patterns and risk for tobacco-related cancer. | Tanner JA et al. | β | 2017 | β |
| Alternative Sampling Strategies for Cytochrome P450 Phenotyping. | De Kesel PM et al. | β | 2016 | β |
| Attenuated nicotine-like effects of varenicline but not other nicotinic ACh receptor agonists in monkeys receiving nicotine daily. | Cunningham CS et al. | β | 2016 | β |
| Brain Responses to Smoking Cues Differ Based on Nicotine Metabolism Rate. | Falcone M et al. | β | 2016 | β |
| Cessation of alcohol consumption decreases rate of nicotine metabolism in male alcohol-dependent smokers. | Gubner NR et al. | β | 2016 | β |
| CYP2A6 genotyping methods and strategies using real-time and end point PCR platforms. | Wassenaar CA et al. | β | 2016 | β |
| Disposition kinetics and metabolism of nicotine and cotinine in African American smokers: impact of CYP2A6 genetic variation and enzymatic activity. | Benowitz NL et al. | β | 2016 | β |
| Estimations and predictors of non-compliance in switchers to reduced nicotine content cigarettes. | Nardone N et al. | β | 2016 | β |
| Genome-Wide Association of the Laboratory-Based Nicotine Metabolite Ratio in Three Ancestries. | Baurley JW et al. | β | 2016 | β |
| Genome-wide association study of caffeine metabolites provides new insights to caffeine metabolism and dietary caffeine-consumption behavior. | Cornelis MC et al. | β | 2016 | β |
| Metabolomics in epidemiology: from metabolite concentrations to integrative reaction networks. | Fearnley LG et al. | β | 2016 | β |
| Nicotine Metabolism in Young Adult Daily Menthol and Nonmenthol Smokers. | Fagan P et al. | β | 2016 | β |
| Nicotine Metabolite Ratio Is Associated With Lozenge Use But Not Quitting in Smokeless Tobacco Users. | Ebbert JO et al. | β | 2016 | β |
| Novel Association of Genetic Markers Affecting CYP2A6 Activity and Lung Cancer Risk. | Patel YM et al. | β | 2016 | β |
| Precision Medicine for Tobacco Dependence: Development and Validation of the Nicotine Metabolite Ratio. | Allenby CE et al. | β | 2016 | β |
| Racial differences in the relationship between rate of nicotine metabolism and nicotine intake from cigarette smoking. | Ross KC et al. | β | 2016 | β |
| Smokescreen: a targeted genotyping array for addiction research. | Baurley JW et al. | β | 2016 | β |
| The Nicotine Metabolite Ratio is Associated With Early Smoking Abstinence Even After Controlling for Factors That Influence the Nicotine Metabolite Ratio. | Chenoweth MJ et al. | β | 2016 | β |
| A CHRNA5 Smoking Risk Variant Decreases the Aversive Effects of Nicotine in Humans. | Jensen KP et al. | β | 2015 | β |
| A Genome-Wide Association Study of a Biomarker of Nicotine Metabolism. | Loukola A et al. | β | 2015 | β |
| Association of CYP2A6 gene polymorphisms with cigarette consumption: a meta-analysis. | Pan L et al. | β | 2015 | β |
| Biomarkers of Response to Smoking Cessation Pharmacotherapies: Progress to Date. | Mamoun M et al. | β | 2015 | β |
| Biomarkers of tobacco smoke exposure in racial/ethnic groups at high risk for lung cancer. | Fagan P et al. | β | 2015 | β |
| Changes in the rate of nicotine metabolism across pregnancy: a longitudinal study. | Bowker K et al. | β | 2015 | β |
| Decreased Nicotinic Receptor Availability in Smokers with Slow Rates of Nicotine Metabolism. | Dubroff JG et al. | β | 2015 | β |
| Different profiles of carcinogen exposure in Chinese compared with US cigarette smokers. | Benowitz NL et al. | β | 2015 | β |
| Drug Metabolizing Enzyme and Transporter Gene Variation, Nicotine Metabolism, Prospective Abstinence, and Cigarette Consumption. | Bergen AW et al. | β | 2015 | β |
| Effects of cigarette smoking and nicotine metabolite ratio on leukocyte telomere length. | Verde Z et al. | β | 2015 | β |
| Effects of Interaction Between Dopamine D2 Receptor and Monoamine Oxidase A Genes on Smoking Status in Young Men. | Huang CL et al. | β | 2015 | β |
| Harmful effects of nicotine. | Mishra A et al. | β | 2015 | β |
| Menthol cigarette smoking and obesity in young adult daily smokers in Hawaii. | Antonio AM et al. | β | 2015 | β |
| Nicotine Dependence, Nicotine Metabolism, and the Extent of Compensation in Response to Reduced Nicotine Content Cigarettes. | Bandiera FC et al. | β | 2015 | β |
| Nicotine metabolite ratio (3-hydroxycotinine/cotinine) in plasma and urine by different analytical methods and laboratories: implications for clinical implementation. | Tanner JA et al. | β | 2015 | β |
| Pharmacogenetics of nicotine and associated smoking behaviors. | Tanner JA et al. | β | 2015 | β |
| Point mutation of cytochrome P450 2A6 (a polymorphic variant CYP2A6.25) confers new substrate specificity towards flavonoids. | Uno T et al. | β | 2015 | β |
| Rate of nicotine metabolism and smoking cessation outcomes in a community-based sample of treatment-seeking smokers. | Kaufmann A et al. | β | 2015 | β |
| Smoking cessation and the cardiovascular patient. | Prochaska JJ et al. | β | 2015 | β |
| Test-Retest Reliability and Stability of the Nicotine Metabolite Ratio Among Treatment-Seeking Smokers. | Hamilton DA et al. | β | 2015 | β |
| The Nicotine Metabolite Ratio in Pregnancy Measured by trans-3'-Hydroxycotinine to Cotinine Ratio: Characteristics and Relationship With Smoking Cessation. | Vaz LR et al. | β | 2015 | β |
| UGT1A and UGT2B genetic variation alters nicotine and nitrosamine glucuronidation in european and african american smokers. | Wassenaar CA et al. | β | 2015 | β |
| Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. | Lerman C et al. | β | 2015 | β |
| Genetics and smoking. | Loukola A et al. | β | 2014 | β |
| Known and novel sources of variability in the nicotine metabolite ratio in a large sample of treatment-seeking smokers. | Chenoweth MJ et al. | β | 2014 | β |
| Novel CYP2A6 variants identified in African Americans are associated with slow nicotine metabolism in vitro and in vivo. | Piliguian M et al. | β | 2014 | β |
| Organic cation transporter variation and response to smoking cessation therapies. | Bergen AW et al. | β | 2014 | β |
| Pharmacogenetics of nicotine addiction: role of dopamine. | Herman AI et al. | β | 2014 | β |
| Recent advances in MS methods for nicotine and metabolite analysis in human matrices: clinical perspectives. | El-Khoury JM et al. | β | 2014 | β |
| Relationship between cotinine and trans-3'-hydroxycotinine glucuronidation and the nicotine metabolite ratio in Caucasian smokers. | Jacobson GA et al. | β | 2014 | β |
| The Genetics, Neurogenetics and Pharmacogenetics of Addiction. | Demers CH et al. | β | 2014 | β |
| The relationship between the nicotine metabolite ratio and three self-report measures of nicotine dependence across sex and race. | Schnoll RA et al. | β | 2014 | β |
| Alaska Native smokers and smokeless tobacco users with slower CYP2A6 activity have lower tobacco consumption, lower tobacco-specific nitrosamine exposure and lower tobacco-specific nitrosamine bioactivation. | Zhu AZ et al. | β | 2013 | β |
| Biomarkers for smoking cessation. | Bough KJ et al. | β | 2013 | β |
| CHRNA5-A3-B4 genetic variants alter nicotine intake and interact with tobacco use to influence body weight in Alaska Native tobacco users. | Zhu AZ et al. | β | 2013 | β |
| COMT Val158Met modulates subjective responses to intravenous nicotine and cognitive performance in abstinent smokers. | Herman AI et al. | β | 2013 | β |
| Cotinine and trans 3'-hydroxycotinine in dried blood spots as biomarkers of tobacco exposure and nicotine metabolism. | Murphy SE et al. | β | 2013 | β |
| CYP2A6 genotype but not age determines cotinine half-life in infants and children. | Dempsey DA et al. | β | 2013 | β |
| Direct quantitative analysis of nicotine alkaloids from biofluid samples using paper spray mass spectrometry. | Wang H et al. | β | 2013 | β |
| Effect of a nicotine vaccine on nicotine binding to Ξ²2*-nicotinic acetylcholine receptors in vivo in human tobacco smokers. | Esterlis I et al. | β | 2013 | β |
| Effects of cations and anions as aggregating agents on SERS detection of cotinine (COT) and trans-3'-hydroxycotinine (3HC). | Han S et al. | β | 2013 | β |
| Feasibility of identifying the tobacco-related global metabolome in blood by UPLC-QTOF-MS. | Hsu PC et al. | β | 2013 | β |
| High dose transdermal nicotine for fast metabolizers of nicotine: a proof of concept placebo-controlled trial. | Schnoll RA et al. | β | 2013 | β |
| Nicotine kinetics in zebra finches in vivo and in vitro. | Miksys S et al. | β | 2013 | β |
| Nicotine metabolism and addiction among adolescent smokers. | Rubinstein ML et al. | β | 2013 | β |
| Predictors of cessation in African American light smokers enrolled in a bupropion clinical trial. | Faseru B et al. | β | 2013 | β |
| Race, gender, and nicotine metabolism in adolescent smokers. | Rubinstein ML et al. | β | 2013 | β |
| Rapid smoking may not be aversive in schizophrenia. | Williams JM et al. | β | 2013 | β |
| Simultaneous serum nicotine, cotinine, and trans-3'-hydroxycotinine quantitation with minimal sample volume for tobacco exposure status of solid organ transplant patients. | Shu I et al. | β | 2013 | β |
| Stability of the nicotine metabolite ratio in smokers of progressively reduced nicotine content cigarettes. | St Helen G et al. | β | 2013 | β |
| Symptoms of depression and smoking behaviors following treatment with transdermal nicotine patch. | Schnoll RA et al. | β | 2013 | β |
| The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sex. | Zhu AZ et al. | β | 2013 | β |
| Variation in trans-3'-hydroxycotinine glucuronidation does not alter the nicotine metabolite ratio or nicotine intake. | Zhu AZ et al. | β | 2013 | β |
| When is it appropriate to scream fire in a crowded theater or public housing? | Hovell MF et al. | β | 2013 | β |
| CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native people. | Binnington MJ et al. | β | 2012 | β |
| CYP2A6 genetic variation and dexmedetomidine disposition. | Kohli U et al. | β | 2012 | β |
| Determination of tobacco smoke exposure by plasma cotinine levels in infants and children attending urban public hospital clinics. | Dempsey DA et al. | β | 2012 | β |
| DRD1 associations with smoking abstinence across slow and normal nicotine metabolizers. | Lee W et al. | β | 2012 | β |
| Genetic variation in CYP2A6 predicts neural reactivity to smoking cues as measured using fMRI. | Tang DW et al. | β | 2012 | β |
| Glucuronidation of trans-3'-hydroxycotinine by UGT2B17 and UGT2B10. | Chen G et al. | β | 2012 | β |
| Nicotine intake and smoking topography in smokers with bipolar disorder. | Williams JM et al. | β | 2012 | β |
| Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes. | Gold AB et al. | β | 2012 | β |
| Pharmacologic characterization of a nicotine-discriminative stimulus in rhesus monkeys. | Cunningham CS et al. | β | 2012 | β |
| PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6. | McDonagh EM et al. | β | 2012 | β |
| Rapid nicotine clearance is associated with greater reward and heart rate increases from intravenous nicotine. | Sofuoglu M et al. | β | 2012 | β |
| Reproducibility of the nicotine metabolite ratio in cigarette smokers. | St Helen G et al. | β | 2012 | β |
| Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse. | Meyer MR et al. | β | 2011 | β |
| Active and passive cigarette smoking and acute lung injury after severe blunt trauma. | Calfee CS et al. | β | 2011 | β |
| Association of the nicotine metabolite ratio and CHRNA5/CHRNA3 polymorphisms with smoking rate among treatment-seeking smokers. | Falcone M et al. | β | 2011 | β |
| Biomarkers to optimize the treatment of nicotine dependence. | Schnoll RA et al. | β | 2011 | β |
| Design, baseline characteristics, and retention of African American light smokers into a randomized trial involving biological data. | Cox LS et al. | β | 2011 | β |
| Determination of the nicotine metabolites cotinine and trans-3'-hydroxycotinine in biologic fluids of smokers and non-smokers using liquid chromatography-tandem mass spectrometry: biomarkers for tobacco smoke exposure and for phenotyping cytochrome P450 2A6 activity. | Jacob P et al. | β | 2011 | β |
| Immediate consequences of cigarette smoking: rapid formation of polycyclic aromatic hydrocarbon diol epoxides. | Zhong Y et al. | β | 2011 | β |
| Nicotine exposure and metabolizer phenotypes from analysis of urinary nicotine and its 15 metabolites by LC-MS. | Rangiah K et al. | β | 2011 | β |
| Nicotine metabolite ratio predicts smoking topography and carcinogen biomarker level. | Strasser AA et al. | β | 2011 | β |
| Oral fluid nicotine markers to assess smoking status and recency of use. | Scheidweiler KB et al. | β | 2011 | β |
| Pharmacogenetics of alcohol, nicotine and drug addiction treatments. | Sturgess JE et al. | β | 2011 | β |
| Quantification of nicotine, cotinine, trans-3'-hydroxycotinine and varenicline in human plasma by a sensitive and specific UPLC-tandem mass-spectrometry procedure for a clinical study on smoking cessation. | Dobrinas M et al. | β | 2011 | β |
| Racial differences in the relationship between number of cigarettes smoked and nicotine and carcinogen exposure. | Benowitz NL et al. | β | 2011 | β |
| Shorter interpuff interval is associated with higher nicotine intake in smokers with schizophrenia. | Williams JM et al. | β | 2011 | β |
| Systematic review of the relationship between the 3-hydroxycotinine/cotinine ratio and cigarette dependence. | West O et al. | β | 2011 | β |
| The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans. | Bloom J et al. | β | 2011 | β |
| Tobacco use and cessation among women: research and treatment-related issues. | Rahmanian SD et al. | β | 2011 | β |
| A prospective cohort study of biomarkers of prenatal tobacco smoke exposure: the correlation between serum and meconium and their association with infant birth weight. | Braun JM et al. | β | 2010 | β |
| Association between nicotine metabolism and CYP2A6*1 and CYP2A6*4 genotypes in an Iranian population. | Heravi RE et al. | β | 2010 | β |
| Carbamazepine but not valproate induces CYP2A6 activity in smokers with mental illness. | Williams JM et al. | β | 2010 | β |
| Estimation of nicotine dose after low-level exposure using plasma and urine nicotine metabolites. | Benowitz NL et al. | β | 2010 | β |
| Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy. | Lerman C et al. | β | 2010 | β |
| Glucuronidation genotypes and nicotine metabolic phenotypes: importance of functional UGT2B10 and UGT2B17 polymorphisms. | Chen G et al. | β | 2010 | β |
| Higher nicotine levels in schizophrenia compared with controls after smoking a single cigarette. | Williams JM et al. | β | 2010 | β |
| Internet suicide guidelines: report of a life-threatening poisoning using tobacco extract. | Schneider S et al. | β | 2010 | β |
| New CYP2A6 gene deletion and conversion variants in a population of Black African descent. | Mwenifumbo JC et al. | β | 2010 | β |
| Pharmacogenetics of drug dependence: role of gene variations in susceptibility and treatment. | Khokhar JY et al. | β | 2010 | β |
| The effect of menthol containing cigarettes on adult smokers' exposure to nicotine and carbon monoxide. | Wang J et al. | β | 2010 | β |
| Two UK suicides using nicotine extracted from tobacco employing instructions available on the Internet. | Corkery JM et al. | β | 2010 | β |
| Urine menthol as a biomarker of mentholated cigarette smoking. | Benowitz NL et al. | β | 2010 | β |
| Analysis of myosmine, cotinine and nicotine in human toenail, plasma and saliva. | SchΓΌtte-Borkovec K et al. | β | 2009 | β |
| A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo. | Al Koudsi N et al. | β | 2009 | β |
| Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. | Ho MK et al. | β | 2009 | β |
| Counseling to reduce children's secondhand smoke exposure and help parents quit smoking: a controlled trial. | Hovell MF et al. | β | 2009 | β |
| Genetic and environmental influences on the ratio of 3'hydroxycotinine to cotinine in plasma and urine. | Swan GE et al. | β | 2009 | β |
| Increases in tobacco exposure biomarkers measured in non-smokers exposed to sidestream cigarette smoke under controlled conditions. | Bernert JT et al. | β | 2009 | β |
| Longer term exposure to secondhand smoke and health outcomes in COPD: impact of urine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol. | Eisner MD et al. | β | 2009 | β |
| Molecular genetics of nicotine metabolism. | Mwenifumbo JC et al. | β | 2009 | β |
| Nicotine chemistry, metabolism, kinetics and biomarkers. | Benowitz NL et al. | β | 2009 | β |
| Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes. | Ray R et al. | β | 2009 | β |
| Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. | Schnoll RA et al. | β | 2009 | β |
| Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. | Benowitz NL | β | 2009 | β |
| Polymorphism of human cytochrome P450 enzymes and its clinical impact. | Zhou SF et al. | β | 2009 | β |
| Population estimates for biomarkers of exposure to cigarette smoke in adult U.S. cigarette smokers. | Roethig HJ et al. | β | 2009 | β |
| Racial differences in serum cotinine levels of smokers. | Signorello LB et al. | β | 2009 | β |
| Urine nicotine metabolite concentrations in relation to plasma cotinine during low-level nicotine exposure. | Benowitz NL et al. | β | 2009 | β |
| Utility and relationships of biomarkers of smoking in African-American light smokers. | Ho MK et al. | β | 2009 | β |
| A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent. | Ho MK et al. | β | 2008 | β |
| Assessing dimensions of nicotine dependence: an evaluation of the Nicotine Dependence Syndrome Scale (NDSS) and the Wisconsin Inventory of Smoking Dependence Motives (WISDM). | Piper ME et al. | β | 2008 | β |
| Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. | Benowitz NL | β | 2008 | β |
| Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolism. | Mwenifumbo JC et al. | β | 2008 | β |
| Nicotine metabolism in three ethnic/racial groups with different risks of lung cancer. | Derby KS et al. | β | 2008 | β |
| Nicotinic receptors containing the alpha7 subunit: a model for rational drug design. | Sharma G et al. | β | 2008 | β |
| Nicotinic Receptors: Role in Addiction and Other Disorders of the Brain. | Sharma G et al. | β | 2008 | β |
| Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. | Mwenifumbo JC et al. | β | 2008 | β |
| Rate of nicotine metabolism and withdrawal symptoms in adolescent light smokers. | Rubinstein ML et al. | β | 2008 | β |
| Stability of the nicotine metabolite ratio in ad libitum and reducing smokers. | Mooney ME et al. | β | 2008 | β |
| Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. | Patterson F et al. | β | 2008 | β |
| A biopsychosocial approach to examining tobacco-related health disparities among racially classified social groups. | Fernander AF et al. | β | 2007 | β |
| Analysis of [3',3'-d(2)]-nicotine and [3',3'-d(2)]-cotinine by capillary liquid chromatography-electrospray tandem mass spectrometry. | Murphy SE et al. | β | 2007 | β |
| Application of nicotine enantiomers, derivatives and analogues in therapy of neurodegenerative disorders. | Pogocki D et al. | β | 2007 | β |
| Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach. | Fuhr U et al. | β | 2007 | β |
| Characterization and comparison of nicotine and cotinine metabolism in vitro and in vivo in DBA/2 and C57BL/6 mice. | Siu EC et al. | β | 2007 | β |
| CYP2B6 genotype does not alter nicotine metabolism, plasma levels, or abstinence with nicotine replacement therapy. | Lee AM et al. | β | 2007 | β |
| Gene-gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism. | Ring HZ et al. | β | 2007 | β |
| Genetic variability in CYP2A6 and the pharmacokinetics of nicotine. | Mwenifumbo JC et al. | β | 2007 | β |
| Nicotine metabolism and CYP2A6 activity in a population of black African descent: impact of gender and light smoking. | Mwenifumbo JC et al. | β | 2007 | β |
| Non-nicotinic therapies for smoking cessation. | Siu EC et al. | β | 2007 | β |
| Overview of the pharmacogenomics of cigarette smoking. | Ho MK et al. | β | 2007 | β |
| Population pharmacokinetics of nicotine and its metabolites I. Model development. | Levi M et al. | β | 2007 | β |
| Prediction methods for nicotine clearance using cotinine and 3-hydroxy-cotinine spot saliva samples II. Model application. | Levi M et al. | β | 2007 | β |
| Relationship of human toenail nicotine, cotinine, and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol to levels of these biomarkers in plasma and urine. | Stepanov I et al. | β | 2007 | β |
| The growing burden of chronic obstructive pulmonary disease and lung cancer in women: examining sex differences in cigarette smoke metabolism. | Ben-Zaken Cohen S et al. | β | 2007 | β |
| The role of CYP2A6 in the emergence of nicotine dependence in adolescents. | Audrain-McGovern J et al. | β | 2007 | β |
| Chronic pancreatic inflammation induced by environmental tobacco smoke inhalation in rats. | Wittel UA et al. | β | 2006 | β |
| Directly measured secondhand smoke exposure and COPD health outcomes. | Eisner MD et al. | β | 2006 | β |
| Evaluation of urinary trans-3'-hydroxycotinine as a biomarker of children's environmental tobacco smoke exposure. | Matt GE et al. | β | 2006 | β |
| Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. | Malaiyandi V et al. | β | 2006 | β |
| Intraindividual variability of plasma antioxidants, markers of oxidative stress, C-reactive protein, cotinine, and other biomarkers. | Block G et al. | β | 2006 | β |
| Using pharmacokinetics to predict the effects of pregnancy and maternal-infant transfer of drugs during lactation. | Anderson GD | β | 2006 | β |
| Chronic nicotine exposure alters blood-brain barrier permeability and diminishes brain uptake of methyllycaconitine. | Lockman PR et al. | β | 2005 | β |
| Identification of N-(hydroxymethyl) norcotinine as a major product of cytochrome P450 2A6, but not cytochrome P450 2A13-catalyzed cotinine metabolism. | Brown KM et al. | β | 2005 | β |
| Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. | Malaiyandi V et al. | β | 2005 | β |
| Metabolism and disposition kinetics of nicotine. | Hukkanen J et al. | β | 2005 | β |
| Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. | Anderson GD | β | 2005 | β |
| Environmental and genetic determinants of tobacco use: methodology for a multidisciplinary, longitudinal family-based investigation. | Swan GE et al. | β | 2003 | β |